Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No link found between pneumonitis in breast cancer patients and taxane-based chemotherapies

17.11.2004


Researchers at The University of Texas M. D. Anderson Cancer Center have shown that breast cancer patients treated with taxane-based chemotherapies and radiation are not at increased risk of developing a dangerous lung condition involving the inflammation of lung tissue, pneumonitis, according to a study published in the Nov. 17 issue of the Journal of the National Cancer Institute.



These results are vitally important, says Thomas Buchholz, M.D., the study’s corresponding author, because both radiation and taxanes-based chemotherapies, including Taxotere and Taxol, have proven effective in the treatment and improved survival of selected patients with breast cancer. In addition, these results disprove a previous smaller study that had suggested the dangerous correlation between taxanes, radiation treatment and lung injury. "We had the unique opportunity to investigate and clearly focus on the question of whether or not taxanes increase radiation induced lung complications," says Buchholz, professor in the Department of Radiation Oncology at M. D. Anderson. "Both taxanes and radiation therapy are critically important in the treatment of patients whose disease has spread beyond the breast.

"The first study showed higher rates of toxicity and received a great deal of attention within the medical community. We were concerned that oncologists might have some reluctance in giving these appropriate treatments. With this study, we wanted to try and determine if we could alleviate the fears of both the physicians administering, and the patients receiving these potentially life-saving treatments."


The research, led by Tse-Kuan Yu, M.D., Ph.D., a resident in radiation oncology at M. D. Anderson and the study’s principal investigator, analyzed 189 breast cancer patients who had been enrolled in a prospective Phase III randomized trial. The patients had received either four cycles of paclitaxel (Taxol) followed by four cycles of 5-flourouracil, doxorubicin and clyclophsphamide (FAC) and then radiation therapy; or eight cycles of FAC followed by radiation.

The researchers were able to review chest X-rays of the women in both groups and could directly evaluate the rates of lung injury. They concluded that there was statistically no difference in the rate of radiation-induced lung toxicity between the two groups of patients; 5 percent in those treated with the paclitaxel-FAC and radiation, compared with 4.5 percent in those treated with FAC and radiation. In addition, the researchers reported that no patients were hospitalized and/or died as a result of pneumonitis. "Fortunately, we discovered that the rates of seriously related lung injury were very, very low in both groups of patients, making us more comfortable in using these potentially curative treatments without any reservations," says Buchholz.

Buchholz and Yu both point out a key difference between the M. D. Anderson research and the earlier study that suggested the lung damage correlation was, in the M. D. Anderson study, chemotherapy and radiation were given sequentially, compared to simultaneous delivery in the smaller study. "It is possible that taxanes and radiation given simultaneously interact to cause increased lung toxicity, but with our delivery, which is more standard practice, we did not see any clinically-relevant damage," says Yu. "Additionally, the sequencing and extended time between the delivery of paclitaxel and the radiation might be of great importance. In our study, four cycles of paclitaxel and then four cycles of FAC were given, followed by surgery and then radiation. Having the buffer window between the Taxol and the radiation might be, in part, cause for why we did not see any lung injury."

Other researchers collaborating on the M. D. Anderson study include: Gary J. Whitman, M.D.; Howard D. Thames, Ph.D.; Aman U. Buzdar, M.D.; Eric A. Strom, M.D.; George H. Perkins, M.D.; Naomi R. Schechter, M.D.; Marsha D. McNeese, M.D.; Shu-Wan Kau; Eva S. Thomas, M.D.; and Gabriel Hortobagyi, M.D.

Laura Sussman | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

New materials: Growing polymer pelts

19.11.2018 | Materials Sciences

Earthquake researchers finalists for supercomputing prize

19.11.2018 | Information Technology

Controlling organ growth with light

19.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>